Zacks Research Comments on Teleflex’s Q3 Earnings (NYSE:TFX)

Teleflex Incorporated (NYSE:TFX) – Research analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for Teleflex in a report released on Wednesday, October 23rd. Zacks Research analyst R. Department now expects that the medical technology company will post earnings of $3.88 per share for the quarter, down from their previous forecast of $3.90. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s FY2025 earnings at $15.34 EPS, Q2 2026 earnings at $4.13 EPS and FY2026 earnings at $16.75 EPS.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.33 by $0.09. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The firm had revenue of $749.70 million for the quarter, compared to analyst estimates of $762.98 million. During the same period in the previous year, the company posted $3.41 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year.

Several other equities analysts have also issued reports on TFX. Royal Bank of Canada boosted their price target on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Truist Financial upped their price objective on Teleflex from $247.00 to $255.00 and gave the company a “hold” rating in a research note on Monday, October 14th. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Finally, Stephens upped their price objective on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $268.86.

Teleflex Trading Down 0.8 %

Shares of TFX opened at $233.65 on Friday. Teleflex has a 12-month low of $177.63 and a 12-month high of $257.85. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $11.01 billion, a price-to-earnings ratio of 41.95, a P/E/G ratio of 2.15 and a beta of 1.16. The stock’s 50-day moving average price is $241.03 and its 200 day moving average price is $223.68.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend was Thursday, August 15th. Teleflex’s payout ratio is currently 24.42%.

Insider Transactions at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $238.93, for a total value of $638,898.82. Following the transaction, the director now directly owns 5,496 shares of the company’s stock, valued at $1,313,159.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.43% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Oregon Public Employees Retirement Fund lifted its holdings in Teleflex by 1.2% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock worth $846,000 after buying an additional 46 shares in the last quarter. Cromwell Holdings LLC lifted its holdings in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock worth $33,000 after buying an additional 49 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Teleflex by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock worth $584,000 after buying an additional 53 shares in the last quarter. Empirical Finance LLC lifted its holdings in Teleflex by 3.9% during the 1st quarter. Empirical Finance LLC now owns 1,564 shares of the medical technology company’s stock worth $354,000 after buying an additional 58 shares in the last quarter. Finally, SRS Capital Advisors Inc. lifted its stake in shares of Teleflex by 0.3% in the 2nd quarter. SRS Capital Advisors Inc. now owns 19,527 shares of the medical technology company’s stock valued at $4,107,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.